• NCIA’s 7th Annual Cannabis Business Summit & Expo takes place December 15-17, 2021, at the Moscone Center in San Francisco.
• The event will showcase more than 80 educational sessions, 125-plus industry speakers, and hundreds of exhibitors under a single roof
• San Francisco Mayor, London Breed, will deliver welcome remarks at the conference on Thursday, December 16th at 10 a.m. PST.
• The Mayor’s appearance at the conference comes as the city celebrates the 30th anniversary of Proposition P, which legalized the use of medical cannabis in San Francisco in 1991.

The National Cannabis Industry Association (“NCIA”), widely recognized as the oldest, largest, and most influential trade association representing the legal cannabis business, will be hosting the 7th Annual Cannabis Business Summit & Expo on December 15-17, 2021. Taking place at San Francisco’s Moscone Center, the conference will showcase over 125 speakers, more than 80 educational sessions, and hundreds of exhibitors across a 12,000 square foot show floor.

The NCIA has recently revealed that San Francisco Mayor, London Breed, will deliver welcoming remarks at the conference, currently scheduled to take place at 10 a.m. PST on Thursday, December 16, 2021. Mayor Breed’s appearance at the 7th Annual Business Summit & Expo comes as San Francisco celebrates the 30th anniversary of the 1991 “Proposition P” ballot initiative, which was instrumental in legalizing the use of medical cannabis in San Francisco, as well as the 25th anniversary of California’s landmark Proposition 216, which extended medical legalization state-wide.

Elected to office in 2018, Mayor Breed, a lifelong member of the Democratic Party, has gained renown for her quest for a more equitable and just San Francisco for all. Thus far in her term, Mayor Breed has been instrumental in creating programs to extend shelter and care for the homeless, as well as provide affordable housing and workforce development programs, in her bid to ensure all San Franciscans have access to a thriving economy.

In addition to Mayor Beard’s appearance, the Cannabis Business Summit & Expo will also highlight cannabis industry leaders and activists, including Troy Datcher, Marvin Washington, Rachael Rapinoe, and Anna Symonds, who will be discoursing on a variety of topics in their positions as the event’s keynote speakers.

In addition, the event marks the debut of Bloom: A Brands Experience. The new “show within a show” entices attendees with a uniquely immersive sensory experience where they can see, touch, and smell products from dozens of brands specializing in flower, vapor, pre-roll, oils, edibles, and more, directly on the show floor

In addition to its keynote speakers, the Cannabis Business Summit will feature over 125+ speakers drawn from a wide range of cannabis sub-sectors. Conference attendees will have the chance to learn about a variety of topics, including ’The Cannabis Law Regulatory Rounds,’ ‘Cannabis Market Trends & Consumer Insights,’ ‘Pathway to Federal Legalization: An Update From DC,’ and ‘A Deep Dive into the Newly Recalibrated Cannabis M&A Market,’ among many others.

Renowned for its reputation as one of the cannabis industry’s most influential B2B trade shows, and the only event to combine a line-up of exclusive educational opportunities, exhibitors, and experiences under a single roof, this year’s Cannabis Business Summit & Expo promises to be a truly unmissable event. In addition, licensed retailers, distributors, infused product manufacturers, and cultivators with a valid state license may attend on a complimentary basis.

For more information about the Cannabis Business Summit & Expo and event registration, visit https://cannabisbusinesssummit.com

Date: November 30-December 2, 2021 Live Streaming Event Traders, shareholders, businesses, financial heads, and investment experts are invited to attend the MoneyShow Canada Virtual Expo being held from November 30- December 2, 2021, as a live streaming event. MoneyShow has been organizing conferences and seminars for over 40 years with a 100,000+ community of investors, financial heads, and businesses looking to gain knowledge and guidance about the latest investment tools, financial trends and opportunities from the stalwarts of the financial arena. The event boasts of a productive platform where attendees can take stock of the trending market ideas, stock picks, live sector analysis, and trade ideas from 30+ top finance market influencers. Traders and businesses can avail this opportunity to find numerous thriving avenues in the stock market for protection and profit. The event can be accessed LIVE from the comfort of one’s home, free of cost. The interactive virtual booths feature message boards, timely research, educational videos, exclusive discounts, prize drawings, and activities that keep the attendees engaged and interested all along! The MoneyShow Canada Virtual Expo is organized for Canadian investors of different skill levels who want to invest across a spectrum of investment sectors. The areas of discussions include a huge gamut of topics including market moves to make before 2022, inflation defence strategies, precious metals, tech and healthcare stocks, timely updates on the economy, and navigating the new normal post-pandemic. Important topics include:

• The Current State of the Economy and Top Stock Picks
• Investing in Real Estate Amid an Economic Recovery
• How to Find Yield in a Low-Rate Environment
• How to Trade Options and Generate a Profitable Income Stream
• When Does a Commodities Boom Turn Into a Supercycle?
• Why Clean Energy Stocks Could Get a Big Boost in 2022
• Navigating Volatility with Fixed-Income Strategies
• Why 2022 Could Be a Big Year for the Cannabis Industry

Get real-time access to the financial stalwarts and industry leaders who will share their ideas, views, and insights in LIVE presentations. New investors can leverage this event as a networking opportunity to build their financial relationships and chat directly with experts and fellow investors. Participants will get access to viewing global market experts and get their queries answered by them and learn new strategies of investments for the upcoming times. For more details on the event please visit https://ibn.fm/R8v0j

• Market analysts place high hopes on the potential of the United Kingdom market
• Growing demand from patients and patient families brought the country’s medical cannabis program to a tipping point
• RYAH is committed to providing valuable insight and transforming patient care through big data and artificial intelligence

After three years of medical cannabis being legal in the United Kingdom, the country has a total of only three patients with a prescription in the entire public system, noted a recent blog from RYAH Group (CSE: RYAH). The article noted that many more patients receive cannabis-derived medications, including flower and cannabis oil, through a growing number of private clinics (https://ibn.fm/mWT2d). The blog provided an overview of the market, observing that “market analysts continue to place high hopes on the potential of the UK market. Yet, in its current form, there remains significant room for improvement to the UK system. With little to no access through the public system and the radically expensive costs associated with privately supplied medical cannabis, many patients are desperate for prescriptions,” RYAH observed. “With growing calls from patients and patient families, the UK’s medical cannabis program is at a tipping point once again. The article pointed out that access to medical cannabis is restrictive in the country, with patients obtaining initial prescriptions through a specialist consultant rather than their general practitioners. Regulations also require patients to try at least two non-cannabis treatments before being eligible for a prescription, which can potentially mean months, if not years, of trial and error before a patient may qualify, the company reported. However, “the most challenging condition within the UK’s medical cannabis policies is the requirement for published evidence,” the blog states. “Medical cannabis may only be prescribed if there is published scientific support for its therapeutic benefits. Most people familiar with cannabis research will appreciate the complications caused by this policy. Patient access around the world suffers because there is a lack of research.” The country is ready for change, RYAH reports. “In 2020, Prohibition Partners suggested the UK market could reach £2.31 billion ($3.13 billion US) by 2024. Statista offered an updated estimate in 2021, predicting the market would hit $1.29 billion US by 2024. At the current pace, these numbers seem unattainable. But change is coming. “The UK public is firmly behind medical cannabis, with more than three-quarters supportive of legal access,” the article continued. “With the growing public outcry following continued reports that the government is refusing access to this valuable therapy, change is in the air.” The leading data technology company in plant-based medicine, RYAH is committed to providing valuable insight and transforming patient care through big data and artificial intelligence. The company is working to unearth breakthrough discoveries that will reshape the understanding of plant-based medicines. For more information, visit the company’s website at www.RYAHGroup.com. NOTE TO INVESTORS: The latest news and updates relating to RYAH are available in the company’s newsroom at https://ibn.fm/RYAH

• Plant-based food consumers are a growing market sector, increasing their purchases at a rate almost 2.5 times the growth of the overall foods market during the past two years
• Plant-based community brand builder PlantX Life Inc. is becoming a growing global presence as part of its efforts to become a one-stop shopping source of products and information about the plant-based lifestyle
• PlantX has physical store presence in Canada and the U.S., as well as one in Israel that will open before the end of the year
• The company’s e-commerce platform recently added a subscription service that caters to recurring customer services, providing discounts for automatically renewable weekly, biweekly, or monthly product shipments
• PlantX has recruited 18 social media influencers to help it market its brand to a larger segment of consumers
• The company uses a weekly podcast series, YouTube channel videos and an informative blog to help build education about the ecosystem among like-minded fans of the lifestyle

Plant-based lifestyle e-retailer and educator PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) recently announced the expansion of its online sales offerings to include discounts for shoppers who subscribe for recurring service. The Nov. 22 announcement states customers who arrange automatic fulfillments for recurring deliveries of any product on the PlantX website will be able to design personalized shopping plans for their favorite products with a weekly, biweekly or monthly refresher. “The new subscription service aims to overcome potential barriers to a healthy lifestyle such as time and cost,” PlantX Founder Sean Dollinger stated (https://ibn.fm/2SMXG). PlantX’s focus on serving the interests of the plant-based community and providing education about its lifestyle benefits to those exploring it in North America are helping the company tap into a relatively new and growing food industry. Plant-based food dollar sales grew 43 percent in the past two years, at a rate almost 2.5 times faster than total food sales from 2018 to 2020, according to a report issued by Good Food Institute analysts earlier this year. The report found that the retail market for plant-based foods has risen to $7 billion, penetrating 57 percent of U.S. households (https://ibn.fm/qOBPj). Bloomberg Intelligence valued the global market for plant-based foods at $29.4 billion in 2020 and predicted that it will exceed $162 billion within the next decade, growing at a rate of 451 percent (https://ibn.fm/PGRD7). PlantX launched a new initiative this year to market itself to those consumers adopting aspects of the plant-based wellness lifestyle, drawing on the power of social media to get its brand more squarely in front of shoppers. The company has engaged select “micro-influencers” on social media platforms including TikTok and Twitter, hiring 18 influencers for limited periods to post content and provide coverage of PlantX news releases to their dedicated audiences. “We live in a time where brands and companies can significantly boost their popularity with viral content focused on social media apps,” PlantX Chief Marketing Officer Alex Hoffman stated in the Nov. 22 announcement. In addition to its e-commerce sales, PlantX has been expanding its XMarket retail store outlets, recently celebrating the grand opening of a store in the San Diego area and another in Venice Beach, which add to the company’s flagship store and dining outlet in Squamish, British Columbia. Additional stores are expected soon in Tel Aviv, Israel, and in Toronto and Ottawa, Canada (https://ibn.fm/W8E41). As part of its efforts to become the plant-based community’s go-to one-stop-shopping hub, PlantX’s educational efforts have grown to include a weekly podcast, blog and YouTube presence, where tips on healthy diet choices, plant-growing wisdom and how to understand the ecosystem of the growing community abound. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• RWB is set to release its Q3 financial results on November 29, 2021
• A conference call will follow this release on November 30, 2021, at 5:00 PM ET to discuss these results, the company’s operations, upcoming events, and a Q&A session
• A replay of the call will be available for 90 days, starting three hours after the conclusion
• RWB is increasingly optimistic about its Q3 performance following growth in revenue from Q1 to Q2, along with strategic investments that would allow for Q3 growth

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF) just announced that it will be releasing its third-quarter (“Q3”) 2021 financial results on Monday, November 29, 2021, after market close. The company will also hold management discussions and analyses (“MD&A”) and other subsequent events following the release (https://ibn.fm/6MuEP). This will mark Christopher Ecken’s first financial release, having joined RWB as its new Chief Financial Officer (“CFO”) back in October 2021 (https://ibn.fm/Xze2a). A conference call is also scheduled for Tuesday, November 30, 2021, at 5:00 PM ET. Here, Brad Rogers, RWB’s Chief Executive Officer (“CEO”), will introduce Mr. Ecken, after which they will discuss the company’s Q3 2021 results, operations, and upcoming events. The conference will also feature a Q&A session with the company’s management, during which attendees will have the opportunity to ask them questions on various topics, including the company’s Q3 financial performance. RWB is optimistic about its Q3 performance. During the Q2 2021 announcement back in August 2021, Mr. Rogers was keen to acknowledge that the company was making significant strides that would play an integral role in its Q3 financial performance. “We continue to make great strides with our branded products and see momentum in Q2, which has teed up Q3 nicely, and will translate into a strong second half,” he noted. “In Florida, after closing the acquisition at the end of April, we have made strategic investments that are allowing us to quickly ramp up capacity as well as complete construction for new store openings before the end of 2021,” he added (https://ibn.fm/FfHav). Mr. Rogers announced that revenue for the second quarter was up by 13% from the previous quarter, along with several significant raw material inventory purchases geared towards supporting growth for Q3, in anticipation of new branded product line launches. Those interested in the announcement can listen online and ask questions via this webcast link:  https://ibn.fm/hQoeY. (Questions during the Q&A will be accepted only via this link.) Dial-in numbers for the conference call for listening only are:

1. 877-705-6006
2. 201-689-8557

A recording of the call will be available approximately three hours following the conference call at https://ir.redwhitebloom.com/  The call will also be available for replay for 90 days, starting three hours after the conclusion of the call. Simply dial 877-660-6853 or 201-612-7415 and enter access ID: 13725118. Going forward, RWB will be announcing dates of earnings reports 30 days before their release. This is one of several new operating procedures to be implemented by Christopher Ecken, RWB’s new CFO. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• People with eating disorders know all about the difficulties faced during holiday celebrations and their association with heavy eating
• The fall-winter holiday season can also adversely affect people suffering from certain chronic pains, as temperatures and pressure changes can increase pain sensitivity
• Tryp is looking to help alleviate problems associated with eating disorders and chronic pain through its psilocybin-based drug program that focuses on conditions with high unmet needs
• The company has submitted several IND applications for Phase 2a studies evaluating TRP-8802’s effectiveness in patients with chronic pain and select eating disorders

There is no denying that food is a massive part of the holiday season. With this year’s Thanksgiving celebration kicking off the fall-winter holiday season that will stretch until New Year’s Day, Americans are likely to go all out foodwise, as is tradition. However, for people with eating disorders, the holiday season can constitute a major challenge. “Holidays may trigger eating disordered behaviors and disordered eating due to the set of stressors that the holidays present; relationship stress, travel, finances, and holiday fatigue are the usual culprits,” explains Cecille Ahrens, a psychotherapist and addiction specialist (https://ibn.fm/kflMr). Research suggests that stress pushes people living with eating disorders, including binge-eating disorder (“BED”), toward overeating as they seek to escape from reality and self-awareness. Unfortunately, this means that this year’s holiday season, as with all others before it, may exacerbate the situation among those suffering from eating disorders, causing them to eat even more. At the same time, the fall-winter holiday season can also adversely impact those suffering from chronic pain. Winter, which comes with changes in temperature, pressure, and moisture, can cause chronic pain patients to experience more aches, stiffness, and a limited range of motion. According to the Pontchartrain Orthopedics & Sports Medicine organization, this heightened achiness considerably increases patients’ pain (https://ibn.fm/Yrp8X). The issue is further compounded by the fact that existing FDA-approved chronic pain drugs have limited efficacy and/or significant side effects. Fortunately, positive change may be in the offing for people living with these conditions. Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company pursuing the development of novel bioscience solutions that aim to address indications with high unmet needs, is leading the next wave of psychedelic drug development with a laser focus on chronic pain, eating disorders, and other unique conditions. The company has made significant progress as it advances toward the rollout of multiple Phase 2a clinical studies to be conducted in collaboration with the University of Michigan and the University of Florida. The studies will evaluate the safety and preliminary effectiveness of Tryp’s TRP-8802, a non-proprietary 25 mg oral capsule of synthetic psilocybin, for the treatment of fibromyalgia, phantom limb pain syndrome, complex regional pain syndrome, BED, and hypothalamic obesity. In line with a recent response to its Investigational New Drug (“IND”) application, Tryp will focus enrollment of the initial Phase 2a study on patients with BED. In addition, the company will submit an IND application for a separate Phase 2a study evaluating TRP-8802 with hypothalamic obesity (https://ibn.fm/LvpL3). Earlier in November, Tryp also submitted an IND application to evaluate the safety and preliminary effectiveness of TRP-8802 in a Phase 2a clinical trial involving patients with fibromyalgia, a class of chronic pain. Tryp anticipates initiating this study next year subject to a favorable review of the IND application (https://ibn.fm/tTavr). Tryp has already received IND authorization for a Phase 2a clinical trial in phantom limb pain, a type of chronic pain (https://ibn.fm/YpmjK). Tryp expects to use data from the multiple Phase 2a studies, as well as various data sets to support the use of TRP-8803, its proprietary psilocybin-based drug product with a novel route of administration, in Phase 2b studies. Eventually, the company intends to commercialize its drug product, potentially easing the challenges and difficulties that eating disorder patients and people suffering from chronic pain face during the holiday seasons. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• U.S.-based FingerMotion is a technology innovator focused on smart communication applications in China’s mobile-hungry billion-plus population
• The company’s big data services are relatively new in development but already play a significant role in the insurtech industry’s global growth trends
• While most of FingerMotion’s revenues are derived from its SMS and MMS products, executives anticipate its big data services will eventually be the company’s largest driver of profits
• The insurtech industry has already generated record annual deal-making this year as of the third quarter, outpacing all of 2020 by 48 percent

The insurtech industry has turned 2021 into a record year for business, with deals that have already outpaced all of 2020, by approximately 48 percent, as of the end of the third quarter. Analysts at CBInsights reported insurtechs had raised $10.5 billion across 427 deals by the quarter’s end (https://ibn.fm/tyVjH). China communications technology solutions provider FingerMotion (OTCQX: FNGR) plays a part in the trend, inking a big data outlook deal with global insurer Pacific Life early in the year to provide data analytics for Pacific Life’s Re-insurance division, and adding two brands last month that will generate value-add underwriting services by covering mobile consumer device maintenance needs (https://ibn.fm/5CGwk). FingerMotion’s revenue generator is its mobile device tech services division, which grew 142 percent year-over-year in its Telecommunications Products and Services business sector and 25 percent quarterly in its SMS (texting) and MMS (phone photo, video and audio sharing) sectors as of the most recent financial report in October (https://ibn.fm/iZHMG). But the company anticipates the latest insurtech services will begin to come online early next year and generate new revenue channels in several of China’s provinces. “This is the third consecutive quarter of Big Data revenues and we expect it to continue and eventually outpace our existing revenue streams,” CEO Martin Shen stated last month following the financial report. “This quarter was more of a transition to greater profitability as more of our initiatives started contributing to gross margin.” FingerMotion’s trademarked big data platform, Sapientus, provides the power behind the company’s services, handling over half a million transactions daily for its mobile payment and recharge services. Although based in the U.S., FingerMotion is focused on the emerging potential of China’s billion-plus population, more than half of which is avid about communications technology to the point of boosting mobile phone subscriptions higher than the country’s actual total population because of the many consumers that use multiple phones. More than 750 million are described as proximity mobile payment users who pay for goods or services using a mobile phone while visiting in-person at a point-of-sale terminal (https://ibn.fm/tKgGM). Ninety percent of smartphone users in the country want their next device to be 5G-enabled, according to a review by China Internet Watch (https://ibn.fm/bfd4D). For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• InMed Pharmaceuticals released Q1 2022 financial results in which it reported a year-on-year increase in research and development expenses primarily due to increased activities related to INM-755 clinical trials
• The company’s cash, cash equivalents, and short-term investments also grew quarter over quarter from $7.4 million to $15.4 million
• Following the closing of BayMedica’s acquisition, the integrated teams are working together with a focus on launching selected rare cannabinoids, growing revenue, and expanding sales
• InMed has commenced Phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders
• Preclinical data of INM-088, the company’s cannabinol (“CBN”) formulation for the treatment of glaucoma, show CBN’s effectiveness in reducing cell death in retinal ganglion cells

For the three months ending September 30, 2021 (“Q1 2022”), InMed Pharmaceuticals (NASDAQ: INM), a global leader in pharmaceutical development, manufacturing, and commercialization of rare cannabinoids, witnessed positive momentum across all of its programs. And in a business update accompanying the release of its Q1 2022 financial results, the company discussed this momentum in relation to the progress made thus far (https://ibn.fm/LRrGu). On October 13, InMed closed the previously announced (https://ibn.fm/rj9qS) acquisition of BayMedica Inc., in a transaction that created an industry leader in the manufacture and commercialization of rare cannabinoids. The integrated teams are now working together to identify rare cannabinoids in BayMedica’s pipeline for commercialization in the consumer health and wellness industry. “For the duration of fiscal year 2022, we will be focused on growing revenues through the launch of these selected rare cannabinoids, in addition to expanding sales of BayMedica’s Prodiol(R) CBC (cannabichromene) and progressing our existing programs,” commented Eric A. Adams, InMed President and CEO. The management expects to introduce multiple new, rare cannabinoids in the near future, focusing on high demand, attractive margin products, in addition to expanding revenues substantially in the short-to-medium term. Further, the integrated science teams will be looking to explore the therapeutic potential of BayMedica’s novel cannabinoid analogs for incorporation into InMed’s pharmaceutical drug development. With regards to its proprietary IntegraSyn(TM) cannabinoid manufacturing approach, the team is currently focused on process optimization for large-scale, pharmaceutical-grade Good Manufacturing Practice (“GMP”) production of rare cannabinoids. InMed holds that IntegraSyn will be a preferred pharmaceutical production method and may fit perfectly with BayMedica’s chemical synthesis and biosynthesis manufacturing approaches for non-pharmaceutical applications. In addition, September 30 also marked the beginning of the 755-201-EB study, InMed’s Phase 2 clinical trial of INM-755 (cannabinol) cream for the treatment of a group of rare skin disorders scientifically known as Epidermolysis Bullosa (“EB”). The commencement of the study marked the first time cannabinol has advanced to a Phase 2 clinical trial to be evaluated as a therapeutic option for disease treatment. The study, which has ethics and regulatory authority approvals in five countries and is expected to take place across seven countries, namely Austria, Germany, Greece, France, Italy, Israel, and Serbia, follows two completed Phase 1 studies. The Phase 1 studies strongly evidenced the overall safety and tolerability of the INM-755 cream. In addition, preclinical data showed that the cream might help relieve characteristic EB symptoms, including pain and inflammation, as well as potentially restore the skin’s integrity in some EB Simplex patients. Combined, the activities related to the INM-755 clinical trials contributed to the company’s increased research and development (“R&D”) expenses for Q1 2022, which stood at $1.5 million, up from $0.9 million in Q1 2021. InMed has also developed a cannabinol (“CBN”) topical eye drop formulation, INM-088, currently the subject of preclinical studies as a potential treatment for glaucoma. Data from these studies demonstrate CBN’s effectiveness in reducing cell death in retinal ganglion cells, indicating the cannabinoid’s neuroprotective capabilities that may extend vision retention. In addition, preclinical data suggest that CBN reduces intraocular pressure in glaucoma models. On August 17, the company presented at the H.C. Wainwright Ophthalmology Conference detailing these findings. InMed continues to work toward completing the INM-088-based preclinical studies in preparation for human clinical trials. The company anticipates filing regulatory applications in the second half of the 2022 financial year to commence human clinical testing with INM-088. Other key highlights of the report and business update included an international patent application for treating neurodegenerative diseases using rare cannabinoids filed early this month, as well as a notable quarter-over-quarter increase in the company’s cash, cash equivalents, and short-term investments from $7.4 million in Q4 2021 to $15.4 million in Q1 2022. InMed attributed this increase to the July 2 private placement in which the company received net proceeds of approximately $11.0 million. For more information, visit the company’s website at www.InMedPharma.com. NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM

• An ever-increasing demand for energy is fueling the focus on sustainable energy solutions.
• UUUU is proud to produce the raw materials that make numerous clean-energy and advanced technologies possible.
• Energy Fuels began producing rare earths in 2021, which are used in electric vehicles, renewable energy, batteries and other technologies.

As the world becomes more focused on and committed to clean energy and sustainability, companies in every sector are recognizing the importance of advancing ESG (environmental, sustainability, and governance) priorities. A leading U.S.-based uranium mining company Energy Fuels (NYSE American: UUUU) (TSX: EFR) places a high priority on its efforts to produce raw materials that support global clean-energy efforts. “As the world population continues to grow, there is an ever-increasing demand for energy, and renewable sources are the answer to providing sustainable energy solutions, while also protecting the planet from climate change,” states a TWI article. “The take-up of clean energy is not just happening on a national level as cities and states are also creating policies to increase renewable energy use. “In the United States, 29 states have set renewable energy portfolios to mandate that a certain percentage of energy consumed should come from renewable sources, and over 100 cities around the world now use at least 70% renewable energy,” the article continued. “The most important aspect of clean energy are the environmental benefits as part of a global energy future. “While clean, renewable resources also preserve the world’s natural resources, they also reduce the risk of environmental disasters, such as fuel spills or the problems associated with natural gas leaks,” the article states. “With fuel diversification, through different power plants using different energy sources, it is possible to create reliable power supplies to enhance energy security, ensuring there is enough to meet our demands.” With that as a backdrop, Energy Fuels does much more than just product uranium, which is the fuel for nuclear energy, producing 50% of all clean, carbon-free electricity in the U.S. “Energy Fuels is proud to produce the raw materials that make numerous clean energy and advanced technologies possible, all in the U.S. at the highest global standards for health, safety and environmental protection,” noted UUUU president and CEO Mark Chalmers (https://ibn.fm/nLhFh). In addition to producing uranium, the fuel for carbon- and emission-free nuclear energy, UUUU began operations to recover rare earth elements (“REEs”) in 2021, which are used in electric vehicles, renewable energy, batteries and other clean technologies. Also worth noting is that, in 2019, the company was the largest U.S. producer of vanadium, which is used in steel, high-strength alloys and grid-scale batteries. Finally, in addition to its efforts to produce material, Energy Fuels is committed to preserving global resources and addressing climate change through industry-leading recycling programs. Not a company to rest on its laurels, Energy Fuels is also exploring other business opportunities, including evaluation the recovery of medical isotopes for use in emerging cancer therapies from existing process streams. Energy Fuels is the leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant, and began commercial production of REE carbonate in 2021. Its corporate offices are in Lakewood, Colorado, near Denver, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the U.S. today, has a licensed capacity of over 8 million pounds of U3O8 per year and has the ability to produce vanadium when market conditions warrant, as well as REE carbonate and uranium from various uranium-bearing ores. The Nichols Ranch ISR Project is currently on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also on standby and has a licensed capacity of 1.5 million pounds of U3O8 per year. In addition to the above production facilities, Energy Fuels also has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S. and several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. For more information, visit the company’s website at www.EnergyFuels.com. NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

• Hiring the wrong individual or placing a good candidate on the wrong team holds dire consequences for organizations.
• PPI evaluates, improves a company’s workforce, brand and culture by revealing the personality traits and sentiment buried in human expression.
• With PPI, savvy organizations can make better hiring decisions, reduce employment attrition and improve workplace culture.

Hiring the right talent and personality for a job is vital for employees — and employers — to be engaged and happy in the workplace, yet it can be hard to know when the person and position are perfect for each other. According to a Forbes article, artificial intelligence (“AI”) technology may be just what companies need to make those types of decisions (https://ibn.fm/2kqCo). That’s good news for DigiMax Global (CSE: DIGI) (OTC: DBKSF), an artificial intelligence technology and services company, whose Projected Personality Interpreter can be effectively used by employees to identify the ideal employees. “Hiring the wrong individual or placing a good candidate on the wrong team holds dire consequences for organizations, including lost productivity and diminished workplace morale,” Forbes reported. “According to the State of the American Workplace report by Gallup Inc., 51 percent of American workers are ‘not engaged’ in their work and an additional 16 percent are ‘actively disengaged’ in their work. “This dissatisfaction adds up to real money for corporations with Gallup estimating that an actively disengaged employee costs their organization $3,400 for every $10,000 of salary, or 34 percent. Furthermore, in hot job markets, such as the technology sector, employers are also spending heavily on additional benefits such as meals, transportation and fitness facilities. Even with these perks, turnover is high.” The article went on to discuss DIGI’s Projected Personality Interpreter (“PPI”), originally conceived and launched by Darwin Ecosystems, a company that was acquired by DigiMax late last year (https://ibn.fm/e05oY). Based on the Darwin Analytics Engine, PPI evaluates and improves a company’s workforce, brand and culture by revealing the personality traits and sentiment buried in human expression (https://ibn.fm/V896c). By leveraging IBM Watson and a customer algorithm that analyzes applicant responses across 52 different traits and compares those scores with a baseline, PPI can provide HR personnel with complete information that supports and guides decision making and removes bias. With PPI, savvy organizations can make better hiring decisions, reduce employment attrition and improve workplace culture. “Employers can leverage the PPI service to understand if a job applicant has the right mix of personality traits for the role or to work within a specific team,” the article continued. “While many interviews focus on communications skills and previous work history, the PPI measures personality traits such as curiosity, susceptibility to stress and self-discipline levels. In a world that focuses on interviewing for the ‘hard skills’ of a job such as technical proficiency and metrics, it’s been difficult for companies to define interview protocols that uncover skills such as a sense of ethics, cautiousness and cooperation levels.” Employers aren’t the only ones that can use PPI. The platform is available as an app, enabling users to identify the personality projected by their social media footprint as well as blogs and web pages. Users can even submit student essays, research papers, work reports and executive summaries to measure the personality traits projected (https://ibn.fm/qMfTz). DIGI is an official IBM Watson partner, reselling or embedding Watson into applications and solutions that it offers. In addition to its deep expertise in AI, DigiMax’s engineering team boasts extensive experience in other key elements including machine learning, neural language processing, big data and cryptocurrency technology. For more information, visit the company’s website at www.DigiMax-Global.com. NOTE TO INVESTORS: The latest news and updates relating to DBKSF are available in the company’s newsroom at https://ibn.fm/DBKSF